REGENERON PHARMACEUTICALS

Regeneron’s share sale by a director and its silver learning‑excellence award show strong governance and data‑driven training, boosting investor confidence and competitive advantage.

Regeneron’s partnership with the 100 Black Men of America conference shows how pharma’s community engagement drives brand equity, payer wins and higher patient value.

Regeneron faces a new atopic dermatitis threat: Apogee’s APG‑101 offers every‑8‑12‑week dosing versus Dupixent’s bi‑weekly regimen, potentially eroding market share and triggering a patent cliff. Strategic moves—pricing, portfolio expansion, or an A…

Regeneron expands its CytomX partnership, adding new targets and funding to create safer, tumor‑specific bispecific therapies—pushing precision oncology forward with a $4 billion potential milestone value.